PARP inhibition potentiates the cytotoxic activity of C-1305, a selective inhibitor of topoisomerase II, in human BRCA1-positive breast cancer cells

Biochemical Pharmacology

Volumn 84, Issue 10, 2012, Pages 1318-1331

  Wȩsierska Ga̧dek, Józefa ^a   Zulehner, Nora ^a   Ferk, Franziska ^a   Składanowski, Andrzej ^b   Komina, Oxana ^a   Maurer, Margarita ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b GDANSK UNIVERSITY OF TECHNOLOGY   (Poland)

Author keywords

Apoptosis; Caspase 3 activation; Cell cycle; DNA strand breaks; G2 arrest; Potential of mitochondrial membrane

Indexed keywords

BRCA1 ASSOCIATED RING DOMAIN PROTEIN 1; C 1305; CASPASE 3; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE INHIBITOR; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CELL CYCLE; CELL CYCLE G2 PHASE; CELL LINE; CELL PROLIFERATION; CONTROLLED STUDY; DNA REPAIR; DNA STRAND BREAKAGE; DRUG CYTOTOXICITY; DRUG EFFICACY; ENZYME INHIBITION; HUMAN; HUMAN CELL; MITOCHONDRIAL MEMBRANE POTENTIAL; PRIORITY JOURNAL;

ACRIDINES; ANTINEOPLASTIC AGENTS; APOPTOSIS; BRCA1 PROTEIN; BREAST NEOPLASMS; CASPASE 3; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; DNA BREAKS; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FEMALE; HUMANS; POLY(ADP-RIBOSE) POLYMERASES; TOPOISOMERASE II INHIBITORS; TRIAZOLES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84867869806     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2012.07.024     Document Type: Article

References (69)

1. C. DeSantis, R. Siegel, P. Bandi, and A. Jemal Breast cancer statistics, 2011 CA Cancer J Clin 61 2011 409 418
2. R. Siegel, D. Naishadham, and A. Jemal Cancer statistics, 2012 CA Cancer J Clin 62 2012 10 29
3. N.R. Bertos, and M. Park Breast cancer - one term, many entities J Clin Invest 121 2011 3789 3796
4. H.G. Russnes, N. Navin, J. Hicks, and A.L. Borresen-Dale Insight into the heterogeneity of breast cancer through next-generation sequencing J Clin Invest 121 2011 3810 3818
5. M.J. Higgins, and J. Baselga Targeted therapies for breast cancer J Clin Invest 121 2011 3797 3803
6. M.H. Greene Genetics of breast cancer Mayo Clin Proc 72 1997 54 65
7. Y. Miki, J. Swensen, D. Shattuck-Eidens, P.A. Futreal, K. Harshman, and S. Tavtigian A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1 Science 266 1994 66 71
8. M.S. Huen, S.M. Sy, and J. Chen BRCA1 and its toolbox for the maintenance of genome integrity Nat Rev Mol Cell Biol 11 2010 138 148
9. R. Roy, J. Chun, and S.N. Powell BRCA1 and BRCA2: important differences with common interests Nat Rev Cancer 12 2012 372
10. J. Wesierska-Gadek, and A. Skladanowski Therapeutic intervention by the simultaneous inhibition of DNA repair and type I or type II DNA topoisomerases: one strategy, many outcomes Future Med Chem 4 2012 51 72
11. M. Binaschi, F. Zunino, and G. Capranico Mechanism of action of DNA topoisomerase inhibitors Stem Cells 13 1995 369 379
12. E.W. Vogel, A. Barbin, M.J. Nivard, H.F. Stack, M.D. Waters, and P.H. Lohman Heritable and cancer risks of exposures to anticancer drugs: inter-species comparisons of covalent deoxyribonucleic acid-binding agents Mutat Res 400 1998 509 540
13. J.A. Royle, P.D. Baade, D. Joske, J. Girschik, and L. Fritschi Second cancer incidence and cancer mortality among chronic lymphocytic leukaemia patients: a population-based study Br J Cancer 105 2011 1076 1081
14. S. Fulda Targeting apoptosis signaling pathways for anticancer therapy Front Oncol 1-7 2011
15. H.E. Bryant, N. Schultz, H.D. Thomas, K.M. Parker, D. Flower, and E. Lopez Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase Nature 434 2005 913 917
16. H. Farmer, N. McCabe, C.J. Lord, A.N. Tutt, D.A. Johnson, and T.B. Richardson Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy Nature 434 2005 917 921
17. T. Hay, J.R. Matthews, L. Pietzka, A. Lau, A. Cranston, and A.O. Nygren Poly(ADP-ribose) polymerase-1 inhibitor treatment regresses autochthonous Brca2/p53-mutant mammary tumors in vivo and delays tumor relapse in combination with carboplatin Cancer Res 69 2009 3850 3855
18. T. Hay, H. Jenkins, O.J. Sansom, N.M. Martin, G.C. Smith, and A.R. Clarke Efficient deletion of normal Brca2-deficient intestinal epithelium by poly(ADP-ribose) polymerase inhibition models potential prophylactic therapy Cancer Res 65 2005 10145 10148
19. N. McCabe, C.J. Lord, A.N. Tutt, N.M. Martin, G.C. Smith, and A. Ashworth BRCA2-deficient CAPAN-1 cells are extremely sensitive to the inhibition of poly (ADP-Ribose) polymerase: an issue of potency Cancer Biol Ther 4 2005 934 936
20. W.G. Kaelin Jr. The concept of synthetic lethality in the context of anticancer therapy Nat Rev Cancer 5 2005 689 698
21. E.Y. Lasfargues, and L. Ozzello Cultivation of human breast carcinomas J Natl Cancer Inst 21 1958 1131 1147
22. C. Thompson, G. MacDonald, and C.R. Mueller Decreased expression of BRCA1 in SK-BR-3 cells is the result of aberrant activation of the GABP Beta promoter by an NRF-1-containing complex Mol Cancer 10 2011 62
23. J. Wesierska-Gadek, M. Gueorguieva, and M. Horky Roscovitine-induced up-regulation of p53AIP1 protein precedes the onset of apoptosis in human MCF-7 breast cancer cells Mol Cancer Ther 4 2005 113 124
24. J. Wesierska-Gadek, D. Schloffer, M. Gueorguieva, M. Uhl, and A. Skladanowski Increased susceptibility of poly(ADP-ribose) polymerase-1 knockout cells to antitumor triazoloacridone C-1305 is associated with permanent G2 cell cycle arrest Cancer Res 64 2004 4487 4497
25. J. Wesierska-Gadek, M. Gueorguieva, C. Ranftler, and G. Zerza-Schnitzhofer A new multiplex assay allowing simultaneous detection of the inhibition of cell proliferation and induction of cell death J Cell Biochem 96 2005 1 7
26. H. Kovar, G. Jug, D. Printz, S. Bartl, G. Schmid, and J. Wesierska-Gadek Characterization of distinct consecutive phases in non-genotoxic p53-induced apoptosis of Ewing tumor cells and the rate-limiting role of caspase 8 Oncogene 19 2000 4096 4107
27. J. Wesierska-Gadek, and G. Schmid Overexpressed poly(ADP-ribose) polymerase delays the release of rat cells from p53-mediated G(1) checkpoint J Cell Biochem 80 2000 85 103
28. L.L. Vindelov Flow microfluorometric analysis of nuclear DNA in cells from solid tumors and cell suspensions. A new method for rapid isolation and straining of nuclei Virchows Arch B: Cell Pathol 24 1977 227 242
29. R.R. Tice, E. Agurell, D. Anderson, B. Burlinson, A. Hartmann, and H. Kobayashi Single cell gel/comet assay: guidelines for in vitro and in vivo genetic toxicology testing Environ Mol Mutagen 35 2000 206 221
30. A. Hartmann, E. Agurell, C. Beevers, S. Brendler-Schwaab, B. Burlinson, and P. Clay Recommendations for conducting the in vivo alkaline Comet assay 4th international comet assay workshop Mutagenesis 18 2003 45 51
31. T. Lindl, and J. Bauer Zell- und Gewebekultur: Einführung in die Grundlagen sowie ausgewählte Methoden und Anwendungen 1994 Gustav Fischer Stuttgart/Jena/New York p. 94
32. J. Wesierska-Gadek, D. Schloffer, V. Kotala, and M. Horky Escape of p53 protein from E6-mediated degradation in HeLa cells after cisplatin therapy Int J Cancer 101 2002 128 136
33. J. Wesierska-Gadek, E. Bohrn, Z. Herceg, Z.Q. Wang, and G. Wurzer Differential susceptibility of normal and PARP knock-out mouse fibroblasts to proteasome inhibitors J Cell Biochem 78 2000 681 696
34. T.C. Chou, and P. Talalay Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors Adv Enzyme Regul 22 1984 27 55
35. M. Reers, T.W. Smith, and L.B. Chen J-aggregate formation of a carbocyanine as a quantitative fluorescent indicator of membrane potential Biochemistry 30 1991 4480 4486
36. E. Gottlieb, S.M. Armour, M.H. Harris, and C.B. Thompson Mitochondrial membrane potential regulates matrix configuration and cytochrome c release during apoptosis Cell Death Differ 10 2003 709 717
37. J. Wesierska-Gadek, M. Gueorguieva, O. Komina, G. Schmid, and M.P. Kramer Signaling of DNA damage is not sufficient to induce p53 response: (re)activation of wt p53 protein strongly depends on cellular context J Cell Biochem 103 2008 1607 1620
38. J.J. Champoux DNA topoisomerases: structure, function, and mechanism Annu Rev Biochem 70 2001 369 413
39. J.C. Wang Moving one DNA double helix through another by a type II DNA topoisomerase: the story of a simple molecular machine Q Rev Biophys 31 1998 107 144
40. O. Sundin, and A. Varshavsky Arrest of segregation leads to accumulation of highly intertwined catenated dimers: dissection of the final stages of SV40 DNA replication Cell 25 1981 659 669
41. A.J. Schoeffler, and J.M. Berger DNA topoisomerases: harnessing and constraining energy to govern chromosome topology Q Rev Biophys 41 2008 41 101
42. J.L. Nitiss Targeting DNA topoisomerase II in cancer chemotherapy Nat Rev Cancer 9 2009 338 350
43. A. Antoniou, P.D. Pharoah, S. Narod, H.A. Risch, J.E. Eyfjord, and J.L. Hopper Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies Am J Hum Genet 72 2003 1117 1130
44. D.T. Bau, Y.C. Mau, and C.Y. Shen The role of BRCA1 in non-homologous end-joining Cancer Lett 240 2006 1 8
45. A.R. Hartman, and J.M. Ford BRCA1 induces DNA damage recognition factors and enhances nucleotide excision repair Nat Genet 32 2002 180 184
46. J.N. Snouwaert, L.C. Gowen, A.M. Latour, A.R. Mohn, A. Xiao, and L. DiBiase BRCA1 deficient embryonic stem cells display a decreased homologous recombination frequency and an increased frequency of non-homologous recombination that is corrected by expression of a brca1 transgene Oncogene 18 1999 7900 7907
47. L. Pellegrini, and A. Venkitaraman Emerging functions of BRCA2 in DNA recombination Trends Biochem Sci 29 2004 310 316
48. M. Sabisz, J. Wesierska-Gadek, and A. Skladanowski Increased cytotoxicity of an unusual DNA topoisomerase II inhibitor compound C-1305 toward HeLa cells with downregulated PARP-1 activity results from re-activation of the p53 pathway and modulation of mitotic checkpoints Biochem Pharmacol 79 2010 1387 1397
49. J. Wesierska-Gadek, Z.Q. Wang, and G. Schmid Reduced stability of regularly spliced but not alternatively spliced p53 protein in PARP-deficient mouse fibroblasts Cancer Res 59 1999 28 34
50. J. Wesierska-Gadek, J. Wojciechowski, and G. Schmid Phosphorylation regulates the interaction and complex formation between wt p53 protein and PARP-1 J Cell Biochem 89 2003 1260 1284
51. P. Lonkar, and P.C. Dedon Reactive species and DNA damage in chronic inflammation: reconciling chemical mechanisms and biological fates Int J Cancer 128 2011 1999 2009
52. J.H. Hoeijmakers DNA damage, aging, and cancer N Engl J Med 361 2009 1475 1485
53. K.K. Khanna, and S.P. Jackson DNA double-strand breaks: signaling, repair and the cancer connection Nat Genet 27 2001 247 254
54. W.D. Heyer, K.T. Ehmsen, and J. Liu Regulation of homologous recombination in eukaryotes Annu Rev Genet 44 2010 113 139
55. D.C. van Gent, J.H. Hoeijmakers, and R. Kanaar Chromosomal stability and the DNA double-stranded break connection Nat Rev Genet 2 2001 196 206
56. M.R. Lieber The mechanism of double-strand DNA break repair by the nonhomologous DNA end-joining pathway Annu Rev Biochem 79 2010 181 211
57. V. Schreiber, F. Dantzer, J.C. Ame, and G. de Murcia Poly(ADP-ribose): novel functions for an old molecule Nat Rev Mol Cell Biol 7 2006 517 528
58. X. Luo, and W.L. Kraus On PAR with PARP: cellular stress signaling through poly(ADP-ribose) and PARP-1 Genes Dev 26 2012 417 432
59. M.E. Moynahan, J.W. Chiu, B.H. Koller, and M. Jasin Brca1 controls homology-directed DNA repair Mol Cell 4 1999 511 518
60. M.E. Moynahan, T.Y. Cui, and M. Jasin Homology-directed DNA repair, mitomycin-c resistance, and chromosome stability is restored with correction of a Brca1 mutation Cancer Res 61 2001 4842 4850
61. D.W. Abbott, M.E. Thompson, C. Robinson-Benion, G. Tomlinson, R.A. Jensen, and J.T. Holt BRCA1 expression restores radiation resistance in BRCA1-defective cancer cells through enhancement of transcription-coupled DNA repair J Biol Chem 274 1999 18808 18812
62. J.E. Meza, P.S. Brzovic, M.C. King, and R.E. Klevit Mapping the functional domains of BRCA1. Interaction of the ring finger domains of BRCA1 and BARD1 J Biol Chem 274 1999 5659 5665
63. T. Ouchi BRCA1 phosphorylation: biological consequences Cancer Biol Ther 5 2006 470 475
64. E.P. Rogakou, D.R. Pilch, A.H. Orr, V.S. Ivanova, and W.M. Bonner DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139 J Biol Chem 273 1998 5858 5868
65. C. Doil, N. Mailand, S. Bekker-Jensen, P. Menard, D.H. Larsen, and R. Pepperkok RNF168 binds and amplifies ubiquitin conjugates on damaged chromosomes to allow accumulation of repair proteins Cell 136 2009 435 446
66. R. Scully, J. Chen, A. Plug, Y. Xiao, D. Weaver, and J. Feunteun Association of BRCA1 with Rad51 in mitotic and meiotic cells Cell 88 1997 265 275
67. A.M. Mendes-Pereira, S.A. Martin, R. Brough, A. McCarthy, J.R. Taylor, and J.S. Kim Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors EMBO Mol Med 1 2009 315 322
68. C.T. Williamson, H. Muzik, A.G. Turhan, A. Zamo, M.J. O'Connor, and D.G. Bebb ATM deficiency sensitizes mantle cell lymphoma cells to poly(ADP-ribose) polymerase-1 inhibitors Mol Cancer Ther 9 2010 347 357
69. L. Ding, G. Getz, D.A. Wheeler, E.R. Mardis, M.D. McLellan, and K. Cibulskis Somatic mutations affect key pathways in lung adenocarcinoma Nature 455 2008 1069 1075